Bavarian Nordic's IMVAMUNE(R) Smallpox Vaccine Highlighted as Success Story in WMD Center's Bio-Response Report Card
Bavarian Nordic A/S
12.10.2011 18:54
---------------------------------------------------------------------------
KVISTGARD, Denmark, 2011-10-12 18:54 CEST (GLOBE NEWSWIRE) --
Bavarian Nordic A/S (Copenhagan:BAVA) today applauded the release of the WMD
Center's Bio-Response Report Card, which concluded that the response to the
threat of smallpox is one of the top success stories for biodefense during the
past decade. The bipartisan Report Card highlights the winning public-private
partnership between Bavarian Nordic and the U.S. Government on the development
of IMVAMUNE(r), a non-replicating smallpox vaccine.
'We are proud that the experts at the WMD Center believe that our partnership
with the U.S. government is a biodefense success story,' said Bavarian Nordic
President and CEO Anders Hedegaard. 'In addition to biodefense, we also have a
strong public-private partnership with the National Cancer Institute. We look
forward to maintaining and growing these partnerships to combat bioterrorism
and advance public health.'
IMVAMUNE(r) is the first vaccine successfully developed under Project BioShield,
a program created by Congress in 2004 to develop and purchase medicines and
vaccines to protect the American public from bioterrorism attacks. Despite its
eradication, bioterrorism experts are concerned about the possibility of an
attack on the U.S. that exposes the population to the smallpox virus.
In 2011, Bavarian Nordic expects to deliver 4 million doses of the vaccine to
the U.S. Strategic National Stockpile, bringing the total inventory to over 6
million doses. Under the BARDA contract, the company will deliver 20 million
doses of IMVAMUNE(r), with an option for 60 million more doses.
According to the report: 'The development of smallpox vaccine suitable for
immune compromised individuals is a textbook example of how the system should
work. NIH funded both the basic and applied science and then transitioned the
program to BARDA, which funded advanced development and procurement. This
generation III smallpox vaccine is now in the Strategic National Stockpile
(SNS) and available for use during an emergency.'
About Bavarian Nordic
Bavarian Nordic is a leader in the development and production of novel vaccines
for the treatment and prevention of life-threatening diseases with a large
unmet medical need. The company's clinical pipeline targets cancer and
infectious diseases, and includes seven development programs. Two programs are
under preparation for Phase III: IMVAMUNE(r), a third-generation smallpox vaccine
that is being developed under a contract with the US government, and PROSTVAC(r),
a treatment for advanced prostate cancer that is being developed under a
collaboration agreement with the National Cancer Institute.
For more information, visit www.bavarian-nordic.com
About the WMD Center and Report Card
The WMD Center is a not-for-profit 501(c)(3) research and education
organization founded in March 2010 by the chair, vice chair, and executive
director of the Congressional Commission on the Prevention of Weapons of Mass
Destruction Proliferation and Terrorism. The WMD Center's Bio-Response Report
Card provides an objective, peer-reviewed, strategic assessment of the U.S.
bio-response enterprise, and offers policy recommendations in seven key areas
of bio-response.
For more information, and to access the Report Card, visit www.wmdcenter.org
Forward-looking statements
This announcement includes 'forward-looking statements' that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or
other information that is not historical information. We undertake no
obligation to publicly update or revise forward-looking statements to reflect
subsequent events or circumstances after the date made, except as required by
law.
CONTACT: Paul Chaplin, Division President,
Infectious Diseases, Bavarian Nordic
Phone 202-288-9220
News Source: NASDAQ OMX
12.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Bavarian Nordic A/S
DÀnemark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0015998017
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Bavarian Nordic A/S
12.10.2011 18:54
---------------------------------------------------------------------------
KVISTGARD, Denmark, 2011-10-12 18:54 CEST (GLOBE NEWSWIRE) --
Bavarian Nordic A/S (Copenhagan:BAVA) today applauded the release of the WMD
Center's Bio-Response Report Card, which concluded that the response to the
threat of smallpox is one of the top success stories for biodefense during the
past decade. The bipartisan Report Card highlights the winning public-private
partnership between Bavarian Nordic and the U.S. Government on the development
of IMVAMUNE(r), a non-replicating smallpox vaccine.
'We are proud that the experts at the WMD Center believe that our partnership
with the U.S. government is a biodefense success story,' said Bavarian Nordic
President and CEO Anders Hedegaard. 'In addition to biodefense, we also have a
strong public-private partnership with the National Cancer Institute. We look
forward to maintaining and growing these partnerships to combat bioterrorism
and advance public health.'
IMVAMUNE(r) is the first vaccine successfully developed under Project BioShield,
a program created by Congress in 2004 to develop and purchase medicines and
vaccines to protect the American public from bioterrorism attacks. Despite its
eradication, bioterrorism experts are concerned about the possibility of an
attack on the U.S. that exposes the population to the smallpox virus.
In 2011, Bavarian Nordic expects to deliver 4 million doses of the vaccine to
the U.S. Strategic National Stockpile, bringing the total inventory to over 6
million doses. Under the BARDA contract, the company will deliver 20 million
doses of IMVAMUNE(r), with an option for 60 million more doses.
According to the report: 'The development of smallpox vaccine suitable for
immune compromised individuals is a textbook example of how the system should
work. NIH funded both the basic and applied science and then transitioned the
program to BARDA, which funded advanced development and procurement. This
generation III smallpox vaccine is now in the Strategic National Stockpile
(SNS) and available for use during an emergency.'
About Bavarian Nordic
Bavarian Nordic is a leader in the development and production of novel vaccines
for the treatment and prevention of life-threatening diseases with a large
unmet medical need. The company's clinical pipeline targets cancer and
infectious diseases, and includes seven development programs. Two programs are
under preparation for Phase III: IMVAMUNE(r), a third-generation smallpox vaccine
that is being developed under a contract with the US government, and PROSTVAC(r),
a treatment for advanced prostate cancer that is being developed under a
collaboration agreement with the National Cancer Institute.
For more information, visit www.bavarian-nordic.com
About the WMD Center and Report Card
The WMD Center is a not-for-profit 501(c)(3) research and education
organization founded in March 2010 by the chair, vice chair, and executive
director of the Congressional Commission on the Prevention of Weapons of Mass
Destruction Proliferation and Terrorism. The WMD Center's Bio-Response Report
Card provides an objective, peer-reviewed, strategic assessment of the U.S.
bio-response enterprise, and offers policy recommendations in seven key areas
of bio-response.
For more information, and to access the Report Card, visit www.wmdcenter.org
Forward-looking statements
This announcement includes 'forward-looking statements' that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or
other information that is not historical information. We undertake no
obligation to publicly update or revise forward-looking statements to reflect
subsequent events or circumstances after the date made, except as required by
law.
CONTACT: Paul Chaplin, Division President,
Infectious Diseases, Bavarian Nordic
Phone 202-288-9220
News Source: NASDAQ OMX
12.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Bavarian Nordic A/S
DÀnemark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0015998017
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------